This page shows the latest statins news and features for those working in and with pharma, biotech and healthcare.
It noted that the drug had only demonstrated "modest" benefits in the data, particularly in patients who also took statins.
That’s a big result, relevant to a huge market of people who currently take statins.
Vascepa's effects in patients already treated with statins to lower their LDL cholesterol, who had various cardiovascular risk factors, including persistent elevated trigylcerides. ... that remains in millions of patients with LDL-C controlled by statin
disease (ASCVD) who were not able to control their cholesterol levels using statins alone. ... injection to high-risk patients who cannot control cholesterol levels using statins alone.
Praluent (alirocumab) to high-dose statins reduced cardiovascular events and all-cause mortality compared to statins alone.
and the risk of coronary revascularisation procedures by 22% over a two year-period when added to statin therapy.
More from news
Approximately 11 fully matching, plus 199 partially matching documents found.
In terms of BACE, Prof Roberts said: “Although the drug companies would love to have a drug that you could take like statins against hypercholesterolaemia, to give long-term protection against
Statins - the most widely prescribed medicines on the planet - might not have been the success story they are without high quality pharmacovigilance detecting the risk of rhabdomyolysis and linking it to
Examples of how OTC can help tackle these pressures include the greater availability of statins in some countries and treatments for sexually transmitted diseases that do not require a prescription.
Perhaps best known for being the company that discovered the blockbuster statin Crestor (rosuvostatin), Shionogi has largely restricted its global focus to R&D.
In 1996 new on-patent medicines became exempt unless they were part of classes such as statins to control the impact on spending on 'me-too' drugs.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
To build equivalent marketing capabilities, pharmaceutical companies invested in training, processes and teams to create highly effective marketing machines, as illustrated by the ‘statin’ wars of the late 90’s/early
benefit (eg: statins, PD-1s or TNFs).
We used to work on products such as calcium-channel blockers, statins and ACE inhibitors.
topics, they may see a recommendation to check out an interactive quiz featuring key points of a statin’s label. And since the recommendation is relevant to one of their medical
launched statin.
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...